Myths · 7 min read

Why peptides stop working and when to cycle off

The honest, three-bucket answer to whether you really have to stay on a peptide forever — and what actually happens in your body the moment you stop.

In this article ▾
  1. Why “forever” is the wrong question
  2. Bucket one: the repair crew — stop when the job’s done
  3. Bucket two: the tenants who never leave
  4. Bucket three: the metabolic peptides, where stopping is the whole story
  5. The other reason a peptide “stopped working”
  6. The bottom line

This is the written version of Why Peptides Stop Working — And When To Cycle Off — watch it instead if you’d rather.

“Do you have to take peptides forever?” is one of the most repeated questions in my comments section, and it’s the wrong question — not because the answer is complicated, but because it assumes “peptides” is one thing. It isn’t. Asking how long you stay on a peptide is like asking how long you keep taking drugs generally. Which one? A course of antibiotics and a daily blood-pressure tablet answer that question completely differently, because they’re not doing the same job in the body. Peptides split the same way. Once you sort them by what they’re actually doing rather than by hype, the “forever” question mostly answers itself.

Why “forever” is the wrong question

I spent my working life as a chartered chemical process engineer, which mostly means getting paid to know when to switch a system off before it breaks. That instinct turns out to map neatly onto peptides, because they fall into three functional buckets: peptides that do a repair job and then have nothing left to do, peptides that keep signalling for as long as you keep using them, and peptides that hold a setting rather than fixing anything underneath it. Mix those buckets up and you get exactly the confused, contradictory advice that fills the comment sections on this topic. Sort them properly and each one has a fairly clean answer for when, or whether, to stop.

No dose here — by design This article is about understanding why a peptide’s effect changes over time and what stopping does, not about using a compound. It names no vendor, no source and no dose, and it is not medical advice.

Bucket one: the repair crew — stop when the job’s done

BPC-157 and TB-500 sit in the first bucket, the one I’d call the repair crew. I’ve covered how people stack these two together before, so I won’t re-run that ground here — what matters for this post is the shape of what they’re proposed to do. They’re thought to nudge along tissue repair and blood vessel growth around an injury, and once the tissue is repaired, the job is finished. You don’t keep a construction crew standing around a wall that’s already been built. For a genuine repair peptide, the general logic is: you stop once you’re healed.

The honest complication is what happens if the pain comes straight back the moment you stop. If the tissue actually healed, it generally shouldn’t. If it does come roaring back, the likely explanation isn’t that the peptide “wore off” — it’s that it muted a signal rather than fixing the underlying mechanical problem, and a needle was never going to solve that on its own. It’s also worth being straight about how thin the evidence base still is here. A 2025 narrative review of BPC-157 in musculoskeletal healing found the literature is overwhelmingly preclinical — animal and lab work — with robust human efficacy trials still missing. That doesn’t mean the mechanism is fiction; it means nobody has run a long-term controlled trial of it in humans, so anyone telling you with confidence exactly how long a course “should” run is guessing past the available data, same as I would be.

Free guide · goes with this article The Peptide Storage Reality Check

Five things everybody repeats about storing peptides, checked against approved labels. None of the five survives. Comes with the other three free guides, for one email.

Get the free guides

Bucket two: the tenants who never leave

The second bucket is the one that actually earns the word “cycling.” GHK-Cu and the growth hormone secretagogues — peptides like CJC-1295 and ipamorelin — are typically run continuously, for skin, sleep, or general wellbeing effects, rather than to fix one discrete injury. That continuous use is exactly what causes the effect to fade with time, and the mechanism isn’t mysterious or a sign of a bad batch.

These growth hormone secretagogues work through the ghrelin receptor, a G-protein-coupled receptor, and receptor biology here follows an extremely well-established rule: hit a receptor hard and continuously enough, and the cell responds by pulling some of those receptors off the surface. Structural work on the human ghrelin receptor published in Nature Communications lays out exactly this kind of signalling behaviour, and downregulation under sustained agonism is standard pharmacology for this receptor family, not a surprise unique to peptides. In plain terms: a dose that did a lot in week two can feel like nothing by week ten, and that’s your own physiology adapting, not the compound failing. Cycling — running it, then taking a genuine break — is the practical answer to that adaptation, because it gives the receptor population time to recover.

GHK-Cu carries a second wrinkle worth flagging honestly: the “Cu” is copper, and copper is a metal the body regulates within a fairly narrow range. Running a copper-carrying peptide indefinitely isn’t only a signalling question, it’s also slowly loading a trace metal your body only wants in small amounts. That’s a reason for caution and a limited course rather than an indefinite one, even setting the receptor argument aside.

Bucket three: the metabolic peptides, where stopping is the whole story

Bucket three flips the entire question on its head. The GLP-1 class — semaglutide and the newer multi-receptor agonists — doesn’t repair anything and it isn’t building tolerance in the way bucket two does. It holds a setting: appetite and hunger signalling are turned down for as long as you’re taking it. Stop, and the setting springs back, because the underlying drive was never removed, only suppressed.

That isn’t theoretical. An extension of the STEP 1 trial, published in Diabetes, Obesity and Metabolism, followed people who had lost weight on semaglutide and then stopped taking it, and found they regained about two-thirds of that lost weight within a year. That isn’t a failure of willpower and it isn’t the drug “wearing off” the way a receptor downregulates — it’s the mechanism running in reverse once it’s no longer being applied. If you’re weighing up switching between GLP-1 compounds rather than stopping outright, I’ve written separately about what that transition actually involves.

Retatrutide, the triple-hormone-receptor agonist that keeps coming up in this conversation, belongs firmly in this same bucket, with one extra caveat: it remains investigational. Its phase 2 results were published in the New England Journal of Medicine in 2023, and the phase 3 registrational programme, TRIUMPH, has a published trial design but is not a finished, approved product. I’ve gone through what that compound can and can’t honestly claim in a lot more depth in a separate post, so I won’t repeat the numbers here — the short version for this post is that it belongs with semaglutide in the “stopping brings it back” bucket, not with the repair peptides.

“Forever” was never one answer, because peptides were never one thing.

The other reason a peptide “stopped working”

Before anyone reaches for tolerance or downregulation as the explanation, it’s worth ruling out something far more common and far less interesting: the product itself. Peptides are chemically fragile. Left warm, shaken about, run past their stability window, or simply underdosed from the vial in the first place, and of course the effect fades — that has nothing to do with your receptors and everything to do with what was actually in the vial. I’ve gone through the other side of this — the full list of reasons a peptide can seem to do nothing at all — in a separate post, and it’s worth reading before you conclude your biology is the problem. I take no money from anybody who sells peptides, which is exactly why I’d rather point you at your own storage habits and your supplier’s paperwork before I let you blame your body.

The bottom line

  • Repair peptides (BPC-157, TB-500): stop once you’re healed — there’s no ongoing job left for them to do, and the human long-term data barely exists anyway.
  • Continuous peptides (GHK-Cu, CJC-1295, ipamorelin): cycle, because sustained receptor agonism downregulates by design, and in GHK-Cu’s case there’s a copper load to respect too.
  • Metabolic peptides (semaglutide, retatrutide): these hold a setting rather than fixing anything, so stopping generally means the effect comes back — mechanism, not willpower.

Three buckets, three different relationships with time, and not one single honest answer to “forever.” If a peptide genuinely seems to be doing less than it used to, work through that list in order: rule out the product before you diagnose your own physiology.

Before you buy anything The Peptide Storage Reality Check is free — five things everybody repeats about storing peptides, checked against approved labels. None of the five survives. It comes with the other three free guides for one email. If you want the full method behind them, that’s the Field-Guide Series.

Sources

  1. Wilding et al., Diabetes, Obesity and Metabolism, 2022 — the STEP 1 trial extension: participants regained about two-thirds of the weight they had lost within a year of stopping semaglutide — https://pubmed.ncbi.nlm.nih.gov/35441470/
  2. Structural basis of human ghrelin receptor signalling, Nature Communications, 2021 — the receptor the growth hormone secretagogues act on, and why sustained agonism at a G-protein-coupled receptor produces downregulation as standard pharmacology rather than as a surprise — https://pubmed.ncbi.nlm.nih.gov/34737341/
  3. BPC-157 in musculoskeletal healing — a narrative review, 2025. The evidence base is overwhelmingly preclinical, and robust human efficacy trials are still missing — https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
  4. Jastreboff et al., New England Journal of Medicine, 2023 — the phase 2 trial of retatrutide, the triple-hormone-receptor agonist. Phase 2, and the compound remains investigational rather than approved — https://doi.org/10.1056/NEJMoa2301972
  5. Rationale and design of the TRIUMPH registrational trials of retatrutide, 2025 — the phase 3 programme, described as it was designed rather than as a result — https://pubmed.ncbi.nlm.nih.gov/41090431/

Educational and research purposes only — not medical advice. Peptide Corner does not recommend any vendor, source, or dose. Keep safe, keep skeptical.